Metabolic dysfunction-associated steatohepatitis (MASH)
- Weight loss is the treatment foundation
- Manage diabetes, lipids + cardiovascular risk
- GLP-1–based obesity therapy can improve metabolic drivers
- Resmetirom is an option for selected noncirrhotic fibrotic MASH
- Avoid hepatotoxic alcohol exposure
- Advanced fibrosis/cirrhosis needs hepatology surveillance
Use at a glance
- Weight loss is the treatment foundation
Monitoring / follow-up
- GLP-1–based obesity therapy can improve metabolic drivers
- Advanced fibrosis/cirrhosis needs hepatology surveillance
Choosing treatment
- Resmetirom is an option for selected noncirrhotic fibrotic MASH
Safety / pitfalls
- Manage diabetes, lipids + cardiovascular risk
- Avoid hepatotoxic alcohol exposure
Self-check
- What is a treatment foundation for Metabolic dysfunction-associated steatohepatitis (MASH)?
Weight loss.
- What should generally be avoided in Metabolic dysfunction-associated steatohepatitis (MASH)?
hepatotoxic alcohol exposure.
Drugs used for this (2)
All clinical uses · Open the interactive console ↗
